Skip to main navigation
Sigilon Therapeutics
  • About Us
    • Our Company
      • Leadership
      • Board of Directors
      • Founders
      • Scientific Advisory Board
    • Contact Us
  • Science
    • SLTx PLATFORM
    • Publications
  • Pipeline
  • Patients & Caregivers
    • Overview
    • Diabetes
    • Lysosomal Diseases
  • Investors/Media
    • Investors/Media Home
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQ
      • Email Alerts
  • Inside Sigilon
    • Our Culture
    • Job Opportunities

Quarterly Reports

Show all

2022

Fourth Quarter
  • Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
  • Form 10-K
Third Quarter
  • Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
  • Form 10-Q
Second Quarter
  • Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
  • Form 10-Q
First Quarter
  • Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business Highlights
  • Form 10-Q

2021

Fourth Quarter
  • Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
  • Form 10-K
Third Quarter
  • Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
  • Form 10-Q
Second Quarter
  • Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
  • Form 10-Q
First Quarter
  • Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
  • Form 10-Q

2020

Fourth Quarter
  • Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
  • Form 10-K

Investors/Media

  • Investors/Media Home
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Analyst Coverage
  • Financials & Filings
    • SEC Filings
    • Quarterly Reports
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Investor Resources
    • Investor FAQ
    • Email Alerts

Investor Contact

Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
Robert.windsor@sigilon.com
617.586.3837
 
 

Media Contact

Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
 
 
©2023 Sigilon Therapeutics, Inc.
sigilon logo
The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners.     Privacy Policy